The traditional pharmaceutical commercial model was built for a market that no longer exists. Greater scrutiny of value, more complex customer relationships, new channels of engagement, and mounting pressure on margins are forcing companies to reconsider how they organize, invest, and compete. Numerof’s 2026 Commercial Model Survey Report, based on…
Former Bristol Myers Squibb senior executive brings more than 35 years of global pricing, market access and commercialization experience to Numerof clients Numerof & Associates, a healthcare strategy consulting firm advising organizations across the life sciences ecosystem, today announced that Laurent Carter, former BMS market access senior executive, has joined…
Hinge Health’s $105 million acquisition of Cylinder Health signals a major strategic shift as virtual care companies expand beyond single-condition offerings toward broader chronic care platforms. While consolidation can help employers address point-solution fatigue, true progress isn’t just about bundling single-condition services. Managing Partner Michael Abrams discussed the structural differences…
Recent reports of a potential $400 billion megamerger between AstraZeneca and Bristol Myers Squibb sent shockwaves through the biopharma sector. While the deal appears off, the underlying driver remains clear: Big Pharma’s urgent need to counter looming loss of exclusivity (LOE). In an interview with PharmaVoice, Managing Partner Michael Abrams…
CMS is right to target wasteful spending in Medicare, but there has been much debate surrounding the new WISeR (Wasteful and Inappropriate Service Reduction) Model, and that it takes the wrong approach. By forcing prior authorization (PA) into traditional Medicare and outsourcing reviews to contractors incentivized by claim denials, WISeR…
Veteran pharmaceutical and biotechnology leader brings decades of global commercial and launch expertise to Numerof clients Numerof & Associates, a healthcare strategy consulting firm advising organizations across the life sciences ecosystem, today announced that Ronald Kierpa, a highly respected global commercial leader in pharmaceuticals and biotechnology, has joined the firm…
